Summary

Just-released valvular heart disease guidelines favor transcatheter interventions for the right patient and more shared decision-making among heart teams, physicians and severe aortic stenosis patients with an eye toward types of valves and approaches, and lifetime benefits and risks.

The 2020 ACC/AHA Heart Valve Disease Guidelines mark a change from the 2014 version and 2017 focused update and open a path to more frequent revisions going forward. The guidelines also offer more evidence and insight for physicians on patients 65-80 and people over 80 for whom transfemoral TAVR is now an option.

This panel of five leading experts who treat VHD unpacks the changes around evaluating and testing patients with severe AS, treating patients at comprehensive valve centers, utilizing anticoagulants and why less invasive procedures have replaced surgery for many patients.

 

What You'll Learn

  • Why low-risk TAVR is changing the way symptomatic severe aortic stenosis patients are treated
  • The benefits of the heart team in treating patients with aortic stenosis
  • Which patients benefit most from TAVR vs. SAVR
  • Why thresholds for intervention are lower now thanks to more robust data and lower procedure risks
  • How EvolutTM Low Risk and PARTNER 3 data have expanded recommendations for low-risk AS patients
  • What cardiologists need to do to expand education with colleagues on which patients benefit most from TAVR
 

Target Audience

  • Chiefs/Directors of Cardiology, Cardiothoracic Surgery, Cardiac Surgery and Interventional Cardiology
  • Cardiothoracic Surgeons
  • Cardiac Surgeons
  • Interventional Cardiologists
  • General Cardiologists
  • Imaging Specialists
  • Structural Heart Teams and Coordinators
  • TAVR Teams and Coordinators
  • Cardiology and Health System Administrators
  • Cardiovascular Service Line Directors

Expert Panel

Michael J. Reardon, MD John Preston Erwin, MD Purvi Parwani Mark J. Ricciardi, MD Paul Sorajja, MD
Moderator

Michael J. Reardon, MD

Chair of Cardiovascular Research
Houston Methodist Hospital

John P. Erwin, III, MD

Department of Internal Medicine
NorthShore University HealthSystem

Purvi Parwani, MD

Director, Women’s Cardiovascular Health Clinic
Loma Linda International Heart Institute

Mark J. Ricciardi, MD

Director of Interventional Cardiology & Structural Heart Disease
NorthShore Cardiovascular Institute

Paul Sorajja, MD

Director of the Center for Valve and Structural Heart Disease
Minneapolis Heart Institute at Abbott Northwestern Hospital